Last week’s hot topic on BPH was UroLift System Now Being Tested in BPH Patients with Median Lobe Obstruction written by Magdalena Kegel.
This article was about NeoTract announcing the enrollment of the first patients in the MedLift U.S. IDE trial investigating the safety and effectiveness of the UroLift System for the treatment of people with benign prostatic hyperplasia (BPH) who have an obstructive median lobe.
Dave Amerson, NeoTract’s CEO, also spoke of how the study will advance the understanding of the benefits of the UroLift System. “We are thrilled that the UroLift System has improved the quality of life for thousands, and we look forward to bringing this innovative therapy to even more patients,” he said in the release.
Eligible men, aged 50 or older, interested in participating in the trial can obtain more information through clinicaltrials.gov or by calling (650) 739-5570.